Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion A Study Interrupted

被引：16
|
作者：
Sharfstein, Joshua M. [1 ]
Psaty, Bruce M. [2 ,3 ,4 ,5 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[2] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[4] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[5] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 315卷 / 10期
关键词：
CONFIDENTIALITY; TRIALS;
D O I：
10.1001/jama.2016.1461
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：984 / 986
页数：3
相关论文
共 50 条
  • [31] Serotonin toxicity and/or opioid withdrawal after the first dose of naltrexone/bupropion: an observational study
    Smolinske, Susan C.
    Logothetis, Stefanie
    Seifert, Steven A.
    Warrick, Brandon J.
    Trubetskoy, Kimberly
    Iwanicki, Janetta L.
    Dart, Richard C.
    CLINICAL TOXICOLOGY, 2020, 58 (06) : 565 - 566
  • [32] EVALUATION OF CARDIOVASCULAR RISK IN ELDERLY - FRAMINGHAM STUDY
    KANNEL, WB
    GORDON, T
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1978, 54 (06) : 573 - 591
  • [33] Naltrexone SR/Bupropion SR Combination Therapy Reduced Body Weight and Improved Metabolic Risk Factors
    Rock, Cheryl L.
    Maier, Holly
    Dunayevich, Eduardo
    Kim, Dennis D.
    Perri, Michael G.
    OBESITY, 2009, 17 : S110 - S110
  • [34] Real-World Evidence Study of Naltrexone/Bupropion for Achieving Clinically Significant Weight Loss
    Arora, Mansi
    Rajasekharan, Shruti
    Rohela, Pallavi
    Sandhu, RajanPaul
    Naidu, Rishi
    Hamm, Caroline
    Naidu, Padmaja
    OBESITY, 2024, 32 : 191 - 192
  • [35] Evaluation of cardiovascular risk in the longitudinal phase of the Mediterranean study
    Gil-Guillen, V. F.
    Merino-Sanchez, J.
    Sanchez-Ruiz, T.
    Amoros-Barber, T.
    Aznar-Vicente, J.
    Abellan-Aleman, J.
    Llisterri-Caro, J. L.
    Orozco-Beltran, D.
    Pascual Perez, M.
    Marquez Contreras, E.
    REVISTA CLINICA ESPANOLA, 2009, 209 (03): : 118 - 130
  • [36] Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine
    Botella-Carretero, JI
    Escobar-Morreale, HF
    Martín, I
    Valero, AM
    Alvarez, F
    García, G
    Varela, C
    Cantarero, M
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (03) : 178 - 182
  • [37] Implementation of the Canadian Cardiovascular Society guidelines for perioperative risk assessment and management: an interrupted time series study
    McIsaac, Daniel I.
    Montroy, Joshua
    Gagne, Sylvain
    Johnson, Chris
    Ernst, Jacelyn
    Halman, Samantha
    Oake, Jeffrey
    Chan, James
    Madden, Susan
    Feng, Simon
    Moody, Michelle
    Simard, Cedric Godbout
    Taljaard, Monica
    Foster, Madison
    Fergusson, Dean A.
    Lalu, Manoj M.
    CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2021, 68 (08): : 1135 - 1145
  • [38] Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart Failure
    Chilton, Robert
    Buse, John
    Plutzky, Jorge
    Wang, Whedy
    Strack, Thomas
    Clapper, Brenda
    Harris-Collazo, Raul
    Klassen, Preston
    OBESITY, 2011, 19 : S177 - S177
  • [39] An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
    Wilcox, Charles S.
    Oskooilar, Nader
    Erickson, Janelle S.
    Billes, Sonja K.
    Katz, Barbara B.
    Tollefson, Gary
    Dunayevich, Eduardo
    ADDICTIVE BEHAVIORS, 2010, 35 (03) : 229 - 234
  • [40] Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study
    Naude, James
    Zentner, Ali
    Suresh, Priya
    Bittman, Jesse
    Khan, Nadia A.
    INTERNATIONAL JOURNAL OF OBESITY, 2024, 48 (08) : 1118 - 1125
12345